Ipsen Signs an Exclusive License Agreement with GENFIT for Elafibranor to Treat Primary Biliary Cholangitis

Published: Dec 17, 2021 | Tags: Ipsen, GENFIT, Elafibranor, Primary Biliary Cholangitis

Merck and Ridgeback Publishes the Results of Molnupiravir in the P-III (MOVe-OUT) Trial for the Treatment of COVID-19 in the NEJM

Published: Dec 17, 2021 | Tags: Merck, Ridgeback, Molnupiravir, P-III, MOVe-OUT Trial, COVID-19, NEJM

BioMarin Collaborates with Skyline to Develop and Commercialize AAV Gene Therapies for Genetic Cardiovascular Diseases

Published: Dec 17, 2021 | Tags: BioMarin, Skyline, Gene Therapies, Cardiovascular Diseases

Daiichi Sankyo and Kite’s Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy Receives MHRA’s Approval for the Treatment of Lymphoma in Japan

Published: Dec 17, 2021 | Tags: Daiichi Sankyo, Kite, Yescarta, Axicabtagene Ciloleucel, CAR T-Cell Therapy, MHRA, Approval, Lymphoma, Japan

Pfizer’s Paxlovid (nirmatrelvir and ritonavir) Receives CHMP's Recommendation for the Treatment of COVID-19

Published: Dec 17, 2021 | Tags: Pfizer, Paxlovid, nirmatrelvir, ritonavir, CHMP, COVID-19

Alpine Signs an Exclusive License and Collaboration Agreement with Horizon to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

Published: Dec 17, 2021 | Tags: Alpine, Horizon, Protein-Based Therapies, Autoimmune, Inflammatory Diseases

Takeda Reports Submission of NDA to MHLW for Novavax’s NVX-CoV2373 to Treat COVID-19

Published: Dec 16, 2021 | Tags: Takeda, NDA, MHLW, Novavax, NVX-CoV2373, COVID-19

Apellis and Sobi’s Aspaveli (pegcetacoplan) Receives EC’s Approval for the Treatment of PNH

Published: Dec 16, 2021 | Tags: Apellis, Sobi, Aspaveli, pegcetacoplan, EC, Approval, PNH

BMS’s Orencia (abatacept) Receives the US FDA’s Approval for the Prevention of Acute Graft Versus Host Disease

Published: Dec 16, 2021 | Tags: BMS, Orencia, abatacept, US, FDA, Approval, Acute Graft Versus Host Disease

BioXcel Initiates P-III (TRANQUILITY) Program of BXCL501 for the Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Published: Dec 16, 2021 | Tags: BioXcel, P-III, TRANQUILITY Program, BXCL501, Alzheimer’s Disease

Jazz Reports First Patient Enrollment in P-IIb Clinical Trial of Suvecaltamide for the Treatment of Essential Tremor

Published: Dec 16, 2021 | Tags: Jazz, P-IIb, Clinical Trial, Suvecaltamide, JZP385, Essential Tremor

Johnson & Johnson Receives CHMP's Positive Opinion of COVID-19 Booster Vaccine for the Treatment of COVID-19

Published: Dec 16, 2021 | Tags: Johnson & Johnson, CHMP, Positive Opinion, COVID-19 Booster Vaccine, COVID-19

Ichnos Signs an Exclusive License Agreement with Almirall for ISB 880 to Treat Autoimmune Diseases

Published: Dec 15, 2021 | Tags: Ichnos, Almirall, ISB 880, Autoimmune Diseases

Genentech Reports Results of Polivy (polatuzumab vedotin) in P-III (POLARIX) Study for the Treatment of Diffuse Large B-Cell Lymphoma

Published: Dec 15, 2021 | Tags: Genentech, Polivy, polatuzumab vedotin, P-III, POLARIX Study, Diffuse Large B-Cell Lymphoma

Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-2) Maintenance Study for the Treatment of Ulcerative Colitis

Published: Dec 15, 2021 | Tags: Eli Lilly, Mirikizumab, P-III, LUCENT-2, Maintenance Study, Ulcerative Colitis

Pfizer’s Xeljanz (tofacitinib) Receives US FDA’s Approval for the Treatment of Active Ankylosing Spondylitis

Published: Dec 15, 2021 | Tags: Pfizer, Xeljanz, tofacitinib, US, FDA, Approval, Active Ankylosing Spondylitis

CSL to Acquire Vifor Pharma for ~$11.7B

Published: Dec 15, 2021 | Tags: CSL, Acquire, Vifor Pharma, ~$11.7B

BMS Signs an Exclusive License Agreement with Immatics to Develop and Commercialize IMA401 for the Treatment of Cancer

Published: Dec 15, 2021 | Tags: BMS, Immatics, IMA401, Cancer

Junshi and Coherus Reports Interim Results of Toripalimab in P-III (CHOICE-01) Trial as 1L Treatment for Non-Small Cell Lung Cancer

Published: Dec 14, 2021 | Tags: Junshi, Coherus, Toripalimab, P-III, CHOICE-01 Trial, Non-Small Cell Lung Cancer

AstraZeneca Expands its Manufacturing Partnership with Samsung Biologics for AZD7442 to Treat COVID-19

Published: Dec 14, 2021 | Tags: AstraZeneca, Samsung Biologics, AZD7442, COVID-19

Janssen Presents Results of Teclistamab in (MajesTEC-1) Study for the Treatment of Multiple Myeloma at ASH 2021

Published: Dec 14, 2021 | Tags: Janssen, Teclistamab, MajesTEC-1 Study, Multiple Myeloma, ASH 2021

Arbutus Signs an Exclusive Licensing Agreement with Qilu to Develop and Commercialize AB-729 for the Treatment of Hepatitis B

Published: Dec 14, 2021 | Tags: Arbutus, Qilu, AB-729, Hepatitis B

Lilly Collaborates with Foghorn to Develop Novel Oncology Therapies for the Treatment of Cancer

Published: Dec 14, 2021 | Tags: Lilly, Foghorn, Novel Oncology Therapies, Cancer

Pfizer to Acquire Arena for ~ $6.7B

Published: Dec 14, 2021 | Tags: Pfizer, Acquire, Arena, ~ $6.7B

BMS Entered into a Clinical Collaboration with Antengene to Evaluate ATG-017 + Opdivo (nivolumab) for Advanced Solid Tumors

Published: Dec 13, 2021 | Tags: BMS, Antengene, ATG-017, Opdivo, nivolumab, Advanced Solid Tumors

Jazz and PharmaMar Initiates P-III (LAGOON) Trial of Zepzelca (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer

Published: Dec 13, 2021 | Tags: Jazz, PharmaMar, P-III, LAGOON Trial, Zepzelca, lurbinectedin, Small Cell Lung Cancer

AstraZeneca Presents Results of Calquence in the P-III (ASCEND) Trial for the Treatment of Chronic Lymphocytic Leukaemia at ASH 2021

Published: Dec 13, 2021 | Tags: AstraZeneca, Calquence, P-III, ASCEND, Trial, Chronic Lymphocytic Leukaemia, ASH 2021

Sanofi Presents Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Atopic Dermatitis at RAD 2021

Published: Dec 13, 2021 | Tags: Sanofi, Dupixent, dupilumab, P-III, Trial, Atopic Dermatitis, RAD 2021

AbbVie Entered into a Clinical Trial Collaboration Agreement with SpringWorks to Evaluate ABBV-383 + Nirogacestat for Multiple Myeloma

Published: Dec 13, 2021 | Tags: AbbVie SpringWorks, ABBV-383, Nirogacestat, Multiple Myeloma

Lilly Entered into a Multi-Year Research Collaboration with Regor to Discover, and Commercialize Novel Therapies for Metabolic Disorders

Published: Dec 13, 2021 | Tags: Lilly, Regor, Novel Therapies, Metabolic Disorders

Related Post: PharmaShots Weekly Snapshots (December 06-10, 2021)